- IXICO senior vice-president commercial operations, John Hall, and vice-president health technology, Ken Tubman, are delivering a presentation on Digital Biomarkers in Alzheimer's Disease at the Coalition Against Major Diseases Critical Path Institute's Digital Biomarkers Conference in Bethesda, Maryland.

The conference, titled 'Use of Biosensors in Clinical Trials: Barriers & Solutions to the Current Landscape', will examine the current landscape of the use of Digital Biomarkers in clinical trials of neurodegenerative diseases, the challenges faced and the need for new solutions.

IXICO's presentation describes how wearable devices and mobile phone apps are being used in Cygnus, a real world study of patients with symptoms of cognitive impairment and possible dementia. Cygnus has received favourable opinion from the Research Ethics Committee and recruitment is expected to commence shortly.

Chief executive Professor Derek Hill said: "We are delighted to have been invited to speak at this ground breaking conference. Wearable and mobile devices have the potential to not only advance, but also to transform clinical trials assessing treatments for dementia. Their success, we believe, will also lead to their uptake in clinical practice in the community. The Cygnus study highlights our continued expansion into a broader range of data capture technologies and builds on our existing contribution to public-private partnerships. It also demonstrates our commitment to be a centre of excellence for dementia research and a leading provider of digital technology in brain health."

At 1:58pm: [LON:IXI] IXICO plc share price was +0.5p at 39.5p

Story provided by